Business Context and Reporting Period
Company: Drugs Made In America Acquisition Corp. (DMAA)
Filing Type: Form 8-K (Current Report)
Reporting Date: April 7, 2026
Event: The Company entered into a non-binding Letter of Intent (LOI) with Power Analytics Global Corp. for a de-SPAC transaction.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures for the reporting period. The document focuses on a proposed transaction.
Transaction Valuation: Approximately $1.0 billion (subject to adjustment based on due diligence, capital structure, net debt, working capital, and market conditions).
Material Changes
- Strategic Shift: Initiation of a business combination process with Power Analytics Global Corp., a Delaware corporation.
- Transaction Status: Terms are subject to further negotiation and the execution of a definitive business combination agreement.
Guidance, Outlook, and Risks
Outlook: The Company anticipates the target valuation to be approximately $1.0 billion, though this is not guaranteed.
Risks and Contingencies:
- The transaction is contingent upon the successful negotiation and execution of a definitive agreement.
- Final valuation is subject to adjustments based on due diligence findings, capital structure, net debt, working capital, and prevailing market conditions.
Investor Verification Checklist
- Verify the execution of a definitive Business Combination Agreement following this LOI.
- Confirm the final valuation of Power Analytics Global Corp. after due diligence.
- Review the specific adjustments to the $1.0 billion valuation regarding net debt and working capital.
- Monitor shareholder approval requirements for the proposed de-SPAC transaction.